248 related articles for article (PubMed ID: 35015693)
1. Circulating Tumor DNA in Lymphoma: Principles and Future Directions.
Roschewski M; Rossi D; Kurtz DM; Alizadeh AA; Wilson WH
Blood Cancer Discov; 2022 Jan; 3(1):5-15. PubMed ID: 35015693
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
Lakhotia R; Roschewski M
Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA in Lymphoma.
Kambhampati S; Zain J
Curr Hematol Malig Rep; 2022 Dec; 17(6):298-305. PubMed ID: 36214943
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of circulating tumor DNA in indolent B-cell lymphomas.
Lakhotia R; Roschewski M
Semin Hematol; 2023 Jul; 60(3):164-172. PubMed ID: 37419716
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
Lauer EM; Mutter J; Scherer F
Leukemia; 2022 Sep; 36(9):2151-2164. PubMed ID: 35701522
[TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries.
Alcaide M; Rushton C; Morin RD
Methods Mol Biol; 2019; 1956():383-435. PubMed ID: 30779047
[TBL] [Abstract][Full Text] [Related]
7. Cell-free DNA in large B-cell lymphoma: MRD and beyond.
Sworder BJ; Kurtz DM
Semin Hematol; 2023 Jul; 60(3):142-149. PubMed ID: 37474409
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
Croessmann S; Park BH
Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
[TBL] [Abstract][Full Text] [Related]
9. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
Chae YK; Oh MS
J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
[TBL] [Abstract][Full Text] [Related]
10. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
11. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
12. [Circulating Tumor DNA Analysis in Lymphomas].
Suehara Y
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1209-1213. PubMed ID: 34657049
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.
Koldby KM; Mortensen MB; Detlefsen S; Pfeiffer P; Thomassen M; Kruse TA
J Gastroenterol; 2019 Feb; 54(2):108-121. PubMed ID: 30242476
[TBL] [Abstract][Full Text] [Related]
15. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA: current challenges for clinical utility.
Dang DK; Park BH
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
18. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
[TBL] [Abstract][Full Text] [Related]
19. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.
Rink M; Schwarzenbach H; Riethdorf S; Soave A
World J Urol; 2019 Sep; 37(9):1785-1799. PubMed ID: 30367205
[TBL] [Abstract][Full Text] [Related]
20. Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma.
Huet S; Salles G
JCO Oncol Pract; 2020 Sep; 16(9):561-568. PubMed ID: 32421389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
